The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the subset of 3866 patients with diabetes mellitus, the benefits of clopidogrel over aspirin were even greater.48”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [48]
In the citing paper
“Clopidogrel has been demonstrated to reduce CVD events in diabetic individuals (217).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [217]
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Dennis, M. S. (1996) · The Lancet · Cited by 2,728
Abizaid, A., Kornowski, R., Mintz, G. S., Hong, M. K., Abizaid, A. S., Mehran, R., Pichard, A. D., Kent, K. M., Satler, L. F., Wu, H., et al. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00286-1 · Cited by 458
Mak, K.-H., Moliterno, D. J., Granger, C. B., Miller, D. P., White, H. D., Wilcox, R. G., Califf, R. M., & Topol, E. J. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00118-6 · Cited by 430
Self-citationRoffi, M., Chew, D. P., Mukherjee, D., Bhatt, D. L., White, J. A., Heeschen, C., Hamm, C. W., Moliterno, D. J., Califf, R. M., White, H. D., et al. (2001) · Circulation · doi:10.1161/hc4801.100029 · Cited by 428
Self-citationAbciximab reduces mortality in diabetics following percutaneous coronary intervention
Bhatt, D. L., Marso, S. P., Lincoff, A. M., Wolski, K. E., Ellis, S. G., & Topol, E. J. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00650-6 · Cited by 336
Self-citationAronson, D., Rayfield, E. J., & Chesebro, J. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-4-199702150-00006 · Cited by 305
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“Clopidogrel has been demonstrated to reduce CVD events in diabetic individuals (318).”
BackgroundStandards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Steinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
“The CREDO trial could not assess whether clopidogrel and aspirin treatment beyond 1 year would continue to reduce risk, but the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial, which will include more than 15000 high-risk but stable patients, with a mean…”
BackgroundSelf-citationStandards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Metadata
- Authors
- Bhatt, D. L., Marso, S. P., Hirsch, A. T., Ringleb, P. A., Hacke, W., & Topol, E. J.
- Affiliations
- Cleveland Clinic (US)
- University of Minnesota (US)
- Heidelberg University (DE)
- Corresponding author
- Bhatt, Deepak L
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 90
- Issue
- 6
- Pages
- 625-628
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W2067925813
- Cited by
- 409
- References
- 21
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 10 · 2022: 3 · 2021: 7 · 2020: 10 · 2019: 7 · 2018: 8 · 2017: 6 · 2016: 12 · 2015: 6 · 2014: 19 · 2013: 19 · 2012: 16
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- clopidogrel, aspirin, diabetes mellitus, antiplatelet therapy, acute myocardial infarction, secondary prevention, recurrent ischemic events, aspirin monotherapy, bleeding risk, coronary angioplasty, coronary artery bypass grafting, percutaneous coronary intervention, myocardial infarction recurrence
- MeSH terms
- Clopidogrel, Aged, Aspirin, Diabetes Mellitus, Diabetic Angiopathies, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Patient Readmission, Platelet Aggregation Inhibitors, Predictive Value of Tests, Risk Factors, Ticlopidine, Incidence, Multivariate Analysis, Treatment Outcome, Endpoint Determination, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. https://app.cochat.ai/papers/10.1016/s0002-9149(02)02567-5
- The paper
- Bhatt, D. L., Marso, S. P., Hirsch, A. T., Ringleb, P. A., Hacke, W., & Topol, E. J. (2002). Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. The American Journal of Cardiology. https://doi.org/10.1016/s0002-9149(02)02567-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.